Melanotan II Dosage Guide

Dosage overview

Dosing notes

MT-II has never been FDA-approved for any indication, and no standardized dosing protocol exists for human use. The following reflects protocols used in published research. Clinical research protocols: The Phase I trial used subcutaneous doses of 0.01-0.03 mg/kg, with 0.025 mg/kg identified as optimal for further study (PMID: 8637402). Erectile dysfunction studies used 0.025 mg/kg subcutaneously, approximately 1.5-2.0 mg for a 70-80 kg adult, with doses separated by 48-hour intervals (PMID: 9679884, 11018622). Community-reported protocols involve two phases: a loading phase of 250-500 mcg daily for 1-4 weeks combined with limited UV exposure (10-15 minutes several times per week), followed by maintenance dosing of 500 mcg to 1 mg once or twice weekly. Starting at 100-250 mcg is commonly recommended to assess individual nausea tolerance. Reconstitution: Lyophilized powder is reconstituted with bacteriostatic water only. For a 10 mg vial, adding 2-3 mL produces concentrations of 3.3-5.0 mg/mL. Solutions should be refrigerated at 2-8 degrees C, protected from light, and used within 30 days. Clean vial tops with alcohol swabs. Inject water slowly along the vial wall, then roll gently to dissolve — never shake. Administration routes: Subcutaneous injection is the most bioavailable route. Nasal spray formulations are approximately 40-50% less effective due to limited mucosal absorption, requiring roughly double the dose for equivalent results. Oral administration produces no detectable plasma levels in the melanocortin analog class (PMID: 9113347). All dosing information is presented for educational purposes only. MT-II is not approved for human use. Consult a physician before considering any peptide protocol.

Important safety information

Dosage ranges listed above are based on available research data and reported protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.

• Start at the lowest effective dose and titrate up gradually
• Monitor for side effects, especially during dose increases
• Do not exceed researched dose ranges without medical supervision
• This is a research compound — human dosing guidelines are not FDA-established

Research references

• Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study — Life Sciences (1996) [PubMed]
• Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers — Archives of Dermatology (2004) [PubMed]
• Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study — Journal of Urology (1998) [PubMed]
• Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II — International Journal of Impotence Research (2000) [PubMed]
• Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction — Urology (2000) [PubMed]
• Discovery that a melanocortin regulates sexual functions in male and female humans — Peptides (2005) [PubMed]
• Use of melanotan I and II in the general population — BMJ (2009) [PubMed]
• Intermittent MTII application evokes repeated anorexia and robust fat and weight loss — Peptides (2010) [PubMed]
• Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction — Canadian Journal of Physiology and Pharmacology (2017) [PubMed]
• Melanotan II injection resulting in systemic toxicity and rhabdomyolysis — Clinical Toxicology (2012) [PubMed]
• Melanotan II: a possible cause of renal infarction: review of the literature and case report — CEN Case Reports (2020) [PubMed]
• Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review — International Journal of Dermatology (2017) [PubMed]
• Melanoma associated with the use of melanotan-II — Dermatology (2014) [PubMed]
• Afamelanotide for Erythropoietic Protoporphyria — New England Journal of Medicine (2015) [PubMed]
• Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study — Orphanet Journal of Rare Diseases (2020) [PubMed]